These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 12189241)

  • 1. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
    Curnis F; Sacchi A; Corti A
    J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
    Corti A; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():104-12. PubMed ID: 15650236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
    Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
    Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy.
    Dondossola E; Gasparri AM; Colombo B; Sacchi A; Curnis F; Corti A
    Cancer Res; 2011 Sep; 71(17):5881-90. PubMed ID: 21799030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
    Curnis F; Sacchi A; Borgna L; Magni F; Gasparri A; Corti A
    Nat Biotechnol; 2000 Nov; 18(11):1185-90. PubMed ID: 11062439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
    Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
    Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms.
    Curnis F; Gasparri A; Sacchi A; Cattaneo A; Magni F; Corti A
    Cancer Res; 2005 Apr; 65(7):2906-13. PubMed ID: 15805293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for improving the anti-neoplastic activity of TNF by tumor targeting.
    Corti A
    Methods Mol Med; 2004; 98():247-64. PubMed ID: 15064445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response.
    Seynhaeve AL; Hoving S; Schipper D; Vermeulen CE; de Wiel-Ambagtsheer Ga; van Tiel ST; Eggermont AM; Ten Hagen TL
    Cancer Res; 2007 Oct; 67(19):9455-62. PubMed ID: 17909055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models.
    Gasparri A; Moro M; Curnis F; Sacchi A; Pagano S; Veglia F; Casorati G; Siccardi AG; Dellabona P; Corti A
    Cancer Res; 1999 Jun; 59(12):2917-23. PubMed ID: 10383155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study.
    Gutman M; Sofer D; Lev-Chelouche D; Merimsky O; Klausner JM
    Invasion Metastasis; 1997; 17(4):169-75. PubMed ID: 9778589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.
    Lejeune FJ
    J Clin Invest; 2002 Aug; 110(4):433-5. PubMed ID: 12189235
    [No Abstract]   [Full Text] [Related]  

  • 15. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.
    Bertilaccio MT; Grioni M; Sutherland BW; Degl'Innocenti E; Freschi M; Jachetti E; Greenberg NM; Corti A; Bellone M
    Prostate; 2008 Jul; 68(10):1105-15. PubMed ID: 18437689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
    Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
    Sochanik A; Mitrus I; Smolarczyk R; CichoĊ„ T; Snietura M; Czaja M; Szala S
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.
    Lee TY; Lin CT; Kuo SY; Chang DK; Wu HC
    Cancer Res; 2007 Nov; 67(22):10958-65. PubMed ID: 18006841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined effect of PT-050 (recombinant human TNF) and antitumor drugs on syngeneic murine tumors].
    Nakata K; Yoshida H; Kashimoto S; Sohmura Y; Nakamura S; Taguchi T
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3186-93. PubMed ID: 3096217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer.
    Bellone M; Mondino A; Corti A
    Trends Immunol; 2008 May; 29(5):235-41. PubMed ID: 18375183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.